- Home
- BMRN vs INCY Comparison
BMRN vs INCY Comparison
Compare BMRN & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- INCY
- Stock Information
- Founded
- BMRN 1996
- INCY 1991
- Country
- BMRN United States
- INCY United States
- Employees
- BMRN N/A
- INCY N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- BMRN Health Care
- INCY Health Care
- Exchange
- BMRN Nasdaq
- INCY Nasdaq
- Market Cap
- BMRN 11.3B
- INCY 13.0B
- IPO Year
- BMRN 1999
- INCY 1993
- Fundamental
- Price
- BMRN $57.77
- INCY $86.64
- Analyst Decision
- BMRN Buy
- INCY Buy
- Analyst Count
- BMRN 23
- INCY 20
- Target Price
- BMRN $93.14
- INCY $80.31
- AVG Volume (30 Days)
- BMRN 1.8M
- INCY 1.7M
- Earning Date
- BMRN 10-28-2025
- INCY 10-28-2025
- Dividend Yield
- BMRN N/A
- INCY N/A
- EPS Growth
- BMRN 154.69
- INCY 900.04
- EPS
- BMRN 3.40
- INCY 4.37
- Revenue
- BMRN $3,063,608,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- BMRN $13.32
- INCY $16.26
- Revenue Next Year
- BMRN $9.37
- INCY $11.07
- P/E Ratio
- BMRN $16.97
- INCY $19.84
- Revenue Growth
- BMRN 18.36
- INCY 18.87
- 52 Week Low
- BMRN $52.93
- INCY $53.56
- 52 Week High
- BMRN $90.01
- INCY $87.99
- Technical
- Relative Strength Index (RSI)
- BMRN 48.39
- INCY 64.89
- Support Level
- BMRN $55.99
- INCY $83.41
- Resistance Level
- BMRN $59.79
- INCY $87.99
- Average True Range (ATR)
- BMRN 1.37
- INCY 1.68
- MACD
- BMRN -0.05
- INCY -0.37
- Stochastic Oscillator
- BMRN 46.84
- INCY 70.52
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.